SCHEMBL5065353

SCHEMBL5065353

Cc1cc(F)c(NC(=O)Nc2ccccc2-c2ccccc2)cc1-c1cc2cnccc2n(C)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.45
RAF1 P04049 2/20 0.45
KDR P35968 3/20 0.42
KRAS P01116 1/20 0.42
MAP2K2 P36507 1/20 0.42
MAP2K1 Q02750 1/20 0.42
NTRK1 P04629 2/20 0.42
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
IMPDH2 P12268 1/20 0.39
ALDH1A1 P00352 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 1/20 0.37
DGAT2 Q96PD7 1/20 0.37
GSK3A P49840 2/20 0.36
FLT1 P17948 2/20 0.36
MAPK14 Q16539 2/20 0.36
RET P07949 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065396 0.85 BRAF (0.57) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5061883 0.78 BRAF (0.55) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5066987 0.77 BRAF (0.54) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5065212 0.76 BRAF (0.58) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4420847 0.74 BRAF (0.56) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5067074 0.74 SRC (0.37) BRAFRAF1PDGFRAMAPTMAPK14
SCHEMBL5062493 0.73 BRAF (0.56) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5067060 0.73 BRAF (0.54) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5057730 0.71 BRAF (0.66) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5067066 0.71 BRAF (0.52) BRAFRAF1KDRKRASMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.